# Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

> **NCT04033302** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 30 (estimated)

## Conditions studied

- T-cell Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Lymphoma
- Acute Myeloid Leukemia
- NK Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD7-specific CAR gene-engineered T cells

## Key facts

- **NCT ID:** NCT04033302
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-07-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04033302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04033302, "Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04033302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*